AP 102
Alternative Names: AP102; Somatostatin analogue - Amryt PharmaLatest Information Update: 14 Apr 2023
Price :
$50 *
At a glance
- Originator Amryt Pharma
- Class Pancreatic hormones; Peptides; Pituitary hormone release inhibiting hormones
- Mechanism of Action Corticotropin-releasing hormone inhibitors; Growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acromegaly; Cushing syndrome
Most Recent Events
- 12 Apr 2023 Amryt Pharma has been acquired by Chiesi Farmaceutici
- 28 Jan 2021 No recent reports of development identified for preclinical development in Acromegaly in United Kingdom
- 28 Jan 2021 No recent reports of development identified for preclinical development in Cushing-syndrome in United Kingdom